MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage various intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Primary demo targets were being To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, even though among the list https://annied443rdo6.blog-a-story.com/profile